» Authors » Ryo Atsuta

Ryo Atsuta

Explore the profile of Ryo Atsuta including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 225
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishimaki T, Sasano H, Harada S, Takeshige T, Sandhu Y, Tanabe Y, et al.
J Allergy Clin Immunol Glob . 2025 Feb; 4(2):100410. PMID: 39974310
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may...
2.
Tagaya E, Shinada J, Nagase H, Terada-Hirashima J, Hojo M, Sugihara N, et al.
J Asthma . 2025 Jan; :1-11. PMID: 39874464
Background: Persistent cough bothers many patients with asthma because it worsens their quality of life; therefore, it must be remedied immediately. The efficacy of triple therapy as a first-line treatment...
3.
Atsuta R, Fujii H, Hara Y, Tanaka H, Nakamura K, Obase Y, et al.
Respir Investig . 2024 Dec; 63(1):156-162. PMID: 39708411
Background: No previous studies have compared respiratory clinics and respiratory specialized facilities regarding causative diseases for bloody sputum and hemoptysis in Japan. Methods: We retrospectively compared causative diseases for bloody...
4.
Ishiura Y, Fujimura M, Ogawa H, Hara J, Shintani H, Hozawa S, et al.
Respir Investig . 2024 Dec; 63(1):74-80. PMID: 39644876
Background: Subacute cough is subdivided and distinguished from chronic cough, because post-infectious cough is considered to be the main cause of subacute cough and differs from acute and chronic cough....
5.
Goto A, Harada S, Sasano H, Sandhu Y, Tanabe Y, Abe S, et al.
J Asthma Allergy . 2024 Nov; 17:1173-1186. PMID: 39558969
Purpose: Omalizumab, the anti-IgE monoclonal antibody used to treat severe asthma, reduces asthma exacerbations, hospitalizations, and corticosteroid use. Although allergic asthma is a therapeutic target of omalizumab, omalizumab is not...
6.
Harada S, Harada N, Sasano H, Tanabe Y, Kotajima M, Sato Y, et al.
PLoS One . 2024 Sep; 19(9):e0309981. PMID: 39240983
Background: Oscillometry devices (also termed forced oscillation technique) devices such as MasterScreen-IOS® (Jaeger, Hochberg, Germany) and MostGraph-01® (Chest, Tokyo, Japan) are useful for obtaining physiological assessments in patients with obstructive...
7.
Ishiura Y, Fujimura M, Ogawa H, Hara J, Shintani H, Hozawa S, et al.
Respir Investig . 2024 Mar; 62(3):442-448. PMID: 38522360
Background: Chronic cough is one of the most common symptoms of respiratory diseases and can adversely affect patients' quality of life and interfere with social activities, resulting in a significant...
8.
Sasano H, Harada N, Harada S, Takeshige T, Sandhu Y, Tanabe Y, et al.
Allergol Int . 2023 Jun; 73(1):94-106. PMID: 37336695
Background: Mepolizumab treatment improves symptom control and quality of life and reduces exacerbations in patients with severe eosinophilic asthma. However, biomarkers that predict therapeutic effectiveness must be determined for use...
9.
Sandhu Y, Harada N, Sasano H, Harada S, Ueda S, Takeshige T, et al.
Biomolecules . 2023 Mar; 13(3). PMID: 36979473
Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for...
10.
Kimura S, Yasudo H, Oga A, Fukano R, Matsushige T, Hamano H, et al.
Pathol Int . 2022 Sep; 72(10):506-518. PMID: 36066006
Pandemic influenza virus A(H1N1)pdm09 infection occurred in healthy children and young adults, but asthmatic patients presented more rapid progression of respiratory distress and plastic bronchitis. To investigate the pathogenesis of...